Business Activities
Research and Development
Research
Mochida's Pharmaceutical Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods
As a member of the Pharmaceutical Consortium for Protein Structure Analysis since 2002, the Center has clarified the three-dimensional structure of proteins utilizing the "SPring-8" synchrotron radiation facility.
Development
Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our four major specialities: cardiovascular agents, obstetrics and gynecology, dermatology, and emergency medicine. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.
Pipeline
| Code | Name | Indications | Formulation | Stage | Remarks |
|---|---|---|---|---|---|
| MLD-55 | escitalopram | Depression | Oral | Phase III completed | Licensed-in from Lundbeck (Denmark) |
| MD-0701 | treprostinil | Pulmonary arterial hypertension | Injection | Phase II/III | Originator: United Therapeutics (USA) |
| FSK0808 | G-CSF | Neutropenia | Injection | Preparation for Phase II/III | Biosimilar （Follow-on biologics) Co-development with Fuji Pharma |
| MND-21 | ethyl icosapentate | Non-alcoholic steatohepatitis | Oral | Phase II | |
| MTD-39 | imiquimod | Actinic keratosis | Topical | Phase II | Licensed-in from iNova Pharmaceuticals (Australia) |
| MR-20V | ulinastatin | Threatened Premature Delivery | Vaginal suppository | Phase II | Suspended |
| JR-031 | Human Mesenchymal Stem Cells | GVHD | Injection | Phase I/II | Cellular-based Drug Co-development with JCR |
| MD-0901 | mesalazine | Ulcerative colitis | Oral | Phase I | Licensed-in from Shire Pharmaceuticals Group （UK） |